GLP1R and type 2 diabetes mellitus: The original finding that GLP-1 infusion increased insulin release and reduced fasting plasma glucose and glucagon in Type 2 diabetic subjects [2] resulted in the development of the first GLP-1 receptor agonists, and the recent licensing of exenatide for the treatment of Type 2 diabetes.